Please assess the completion status of the following clinical trial:

Trial Title: Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* To be eligible for participation in the study, patients must meet all of the following inclusion criteria:~  1. Be between the ages of ≥18 and ≤65 years~ 2. Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria with ≥20% bone marrow blasts based on histology or flow cytometry~ 3. Be newly diagnosed and previously untreated~ 4. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2~ 5. Have a serum creatinine level ≤1.8 mg/dL~ 6. Have an alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level ≤5 times upper limit of normal (ULN)~ 7. Have a total bilirubin level ≤2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)~ 8. Have a left ventricular ejection fraction (LVEF) \>45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan~ 9. Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry, for the duration of study participation, and for at least 6 months after the last dose of study drug.~ 10. Be able to comply with the requirements of the entire study.~ 11. Provide written informed consent prior to any study related procedure. (In the event that the patient is re-screened for study participation or a protocol amendment alters the care of an ongoing patient, a new informed consent form must be signed.)~Exclusion Criteria:~* Patients meeting any one of these exclusion criteria will be prohibited from participating in this study.~  1. Received any previous treatment for AML~ 2. Diagnosed with APL-M3 or CBF-AML~ 3. Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting Induction therapy.~ 4. Received \>200 mg/m2 equivalents of daunorubicin~ 5. Have a peripheral blast count of \>30,000/mm3 (may use hydroxyurea as in #3 above)~ 6. Have active central nervous system (CNS) leukemia~ 7. Have evidence of uncontrolled disseminated intravascular coagulation~ 8. Have an active, uncontrolled infection~ 9. Have other life-threatening illness~ 10. Have other active malignancies or diagnosed with other malignancies within the last 6 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia~ 11. Have mental deficits and/or psychiatric history that may compromise the ability to give written informed consent or to comply with the study protocol.~ 12. Are pregnant and/or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Alvocidib and Cytarabine/Daunorubicin (Type: EXPERIMENTAL): The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete